Laurus Labs Limited received FDA approval on August 20, 2026, for the anticoagulant Ticagrelor, marking a significant milestone in the company's expansion of its late-stage pipeline. While this approval broadens access to the cardiovascular agent, market analysts anticipate the entry of a generic will aggressively compress pricing and impact the revenue trajectory of the branded products currently driving growth.